Ratings Pediatrix Medical Group, Inc.

Equities

MD

US58502B1061

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
9.04 ^USD	+1.57%		+0.11%	-2.80%

Mar. 06	Jefferies Cuts Price Target on Pediatrix Medical to $9 From $11, Maintains Hold Rating	MT
Feb. 21	Deutsche Bank Trims Pediatrix Medical Group Price Target to $8 From $9, Maintains Sell Rating	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

Its low valuation, with P/E ratio at 8.49 and 8.26 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
The stock, which is currently worth 2024 to 0.59 times its sales, is clearly overvalued in comparison with peers.
The company's share price in relation to its net book value makes it look relatively cheap.
The company has a low valuation given the cash flows generated by its activity.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company sustains low margins.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
PEDIATRIX MEDICAL GROUP, INC.	-2.80%	747M		B
CVS HEALTH CORPORATION	-14.92%	84.68B		B-
HCA HEALTHCARE, INC.	+13.30%	81.12B		C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.4B		C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.71%	16.73B		B
FRESENIUS SE & CO. KGAA	-3.06%	16.36B		A-
QUEST DIAGNOSTICS INCORPORATED	-2.63%	14.92B		A-
EUROFINS SCIENTIFIC SE	-3.97%	11.66B		A-
FRESENIUS MEDICAL CARE AG	-1.42%	11.72B		A-
PURE HEALTH HOLDING	-31.75%	11.77B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes